- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01024075
Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes
December 1, 2009 updated by: University of Calgary
The Adjunctive Use of a Dexamethasone-Sinufoam Mixture on Endoscopic Sinus Surgery Outcomes: A Randomized, Double-Blind, Placebo-controlled Trial
Dexamethasone added to sinufoam, which is placed in the ethmoid cavity at the completion of endoscopic sinus surgery, will improve sinonasal mucosal healing.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Sinufoam is an FDA approved mixture, which is placed in the ethmoid cavity at the completion of an endoscopic sinus surgery procedure.
Sinufoam prevents scarring and promotes healing of the sinonasal mucosa.
Sinufoam is commonly mixed with saline, which enables it to be liquefied and gently placed into the ethmoid cavity.
Recent practice of adding Dexamethasone to the sinufoam mixture has been hypothesized to promote healing by reducing chronic inflammation associated with CRS.
Using topical dexamethasone mixed into the Sinufoam solution may improve patient care by preventing the systemic effects associated with post-operative systemic steroid use.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Recruiting
- University of Calgary
-
Contact:
- Luke Rudmik, MD
- Phone Number: 05851 403-212-8223
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >18 years old
- Chronic Rhinosinusitis without nasal polyps --- defined according to the AAO guidelines
- Elective "Bilateral" sinus surgery requiring at a minimum of an Uncinectomy, Maxillary Antrostomy, and Anterior Ethmoidectomy.
Exclusion Criteria:
- Uncorrectable coagulopathy
- Emergency procedure
- Unavailable for standard post operative follow-up
- Sinonasal neoplasm resections
- Excessive intra-operative bleeding requiring nasal packing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Saline
Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
|
8cc of Saline mixed with Sinufoam
|
|
ACTIVE_COMPARATOR: Dexamethasone
Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
|
4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sinonasal mucosal healing
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sinonasal quality of life (SNOT-22)
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (ANTICIPATED)
November 1, 2010
Study Completion (ANTICIPATED)
May 1, 2011
Study Registration Dates
First Submitted
November 30, 2009
First Submitted That Met QC Criteria
December 1, 2009
First Posted (ESTIMATE)
December 2, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
December 2, 2009
Last Update Submitted That Met QC Criteria
December 1, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Sinusitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- 22476
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.